Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEO · Real-Time Price · USD
6.00
+0.07 (1.18%)
At close: Sep 4, 2026, 4:00 PM EDT
6.01
+0.01 (0.15%)
After-hours: Sep 4, 2026, 7:30 PM EDT

Abeona Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
25.525.82-3.51.413
Revenue Growth
6280.00%--147.53%-52.87%-70.00%
Gross Profit
-10.18-24.42-34.36-29.2-28-35.73
Operating Income
-83.62-89.45-64.21-48.2-45.26-57.37
Net Income
-62.8971.18-63.73-54.19-43.48-84.94
Earnings Per Share
-1.181.01-1.55-2.53-5.53-21.57
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
146.83191.497.7252.2352.1545.02
Total Debt
19.8724.9723.055.47.639.38
Net Cash (Debt)
126.95166.4474.6746.8344.5235.65
Net Cash Growth
-36.98%122.89%59.47%5.17%24.90%-58.70%
Net Cash Per Share
2.282.521.822.195.669.05

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-76.44-76.33-56.02-37.01-43.48-65.67
Capital Expenditures
-5.09-7.98-2.45-0.33-0.13-4.15
Free Cash Flow
-81.53-84.3-58.46-37.34-43.61-69.82
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-39.90%-----
Operating Margin
-327.64%-1536.91%--1377.14%-3200.64%-1912.33%
Pretax Margin
-306.81%1224.79%--1548.23%-2807.36%-2831.20%
Profit Margin
-246.42%1223.08%--1548.23%-3074.82%-2831.20%
FCF Margin
-319.46%-1448.47%--1066.86%-3084.37%-2327.20%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-4.01----
Forward PE
-231.80----
PS Ratio
13.4449.07-35.4637.4116.47